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Background: The effective management of pain in chronic pancreatitis (CP) remains a thera-
peutic challenge. Analgesic drugs, such as opioids, and the underlying pathology can impair 
gut function. The autonomic nervous system influences hormone secretion and gut motility. 
In healthy volunteers, electrical (using noninvasive transcutaneous vagal nerve stimulation 
[t-VNS]) and physiological (using deep slow breathing [DSB]) modulation of parasympathetic 
tone results in pain attenuation and enhanced gut motility. Thus, the aims were to investigate 
whether t-VNS and DSB could enhance the parasympathetic tone, decrease pain sensitivity and 
improve gut motility in CP.
Patients and methods: A total of 20 patients (12 males, mean age=61 years, range: 
50–78 years) with CP were randomized to short-term (60 minutes) t-VNS and DSB, or their 
placebo equivalent, in a crossover design. Cardiometrically derived parameters of autonomic 
tone, quantitative sensory testing of bone and muscle pain pressure, conditioned pain modulation 
(CPM) and assessments of gastroduodenal motility with ultrasound were performed.
Results: In comparison to sham, t-VNS and DSB increased cardiac vagal tone (CVT) (P<0.001). 
However, no changes in pain pressure thresholds for bone (P=0.95) or muscle (P=0.45) were 
seen. There was diminished CPM (P=0.04), and no changes in gastroduodenal motility were 
observed (P=0.3).
Conclusion: This explorative study demonstrated that t-VNS and DSB increased CVT in 
patients with CP. However, this short-lasting increase did not affect pain sensitivity to musculo-
skeletal pain or gastroduodenal motility. The chronic pain in CP patients is complex, and future 
trials optimizing neuromodulation for pain relief and improved motility are needed.
Keywords: pain, chronic pancreatitis, autonomic nervous system, vagus nerve, gut, motility
Introduction
Chronic pancreatitis (CP) is characterized by fibro-inflammation, and it is often associ-
ated with chronic pain.1 As the disease progresses, exocrine and endocrine insufficiency 
may develop,2,3 necessitating treatment with antidiabetic medication and enzymatic 
supplementation. While these aforementioned complications are relatively straightfor-
ward to treat, chronic pain is more challenging and is associated with reduced quality 
of life and increased health resource utilization.4–6 In the patients where the underlying 
pathology is not amenable to endoscopic intervention or surgery, the treatment of pain is 
largely pharmacological in nature.7 Analgesic monotherapy rarely provided meaningful 
analgesic relief and combination therapy, such as opioids and gabapentoids are therefore 
often needed. However, adverse effects secondary to opioids are common, and therefore, 
achieving a balance between analgesic benefits and such side effects is challenging, 
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particular in patients with other complications such as duode-
nal stenosis, pseudocysts and ongoing pancreatic inflamma-
tion. Notwithstanding the adverse cognitive effects of opioids, 
they may further compromise gastrointestinal (GI) function 
with diminution of motility.8,9 Therefore, there is a pressing 
unmet clinical need for the development of effective alterna-
tives, which ameliorate pain and enhance GI motility in CP.
Normal GI function relies on a bidirectional communication 
from the gut to the central nervous system, delivered in part 
by the autonomic nervous system (ANS). The ANS consists of 
two broadly opposing branches referred to as the sympathetic 
and the parasympathetic nervous systems,10 which integrate 
with the enteric nervous system in the gut. The vagus nerve 
forms the main parasympathetic neural substrate of the ANS, 
while the spinal afferents form the sympathetic nerves.11 Thus, 
in health, there is a delicate balance between sympathetic and 
parasympathetic influences, which is responsible for release of 
hormones, GI motility and the maintenance of homeostasis. A 
paucity of vagal activity has been identified as a pathophysi-
ological feature in a number of disorders related to the GI tract 
including inflammatory bowel disease, functional dyspepsia, 
irritable bowel syndrome and diabetic autonomic neuropathy 
and gastroparesis.12–15 In CP, preliminary studies have postulated 
that autonomic dysfunction may contribute to the complex pain 
and GI dysmotility.16–18 Vagal activity can be therapeutically 
accentuated either physiologically, with deep slow breathing 
(DSB), or electrically, using vagus nerve stimulation (VNS), 
which can be applied invasively or noninvasively through the 
skin. In healthy volunteers, DSB and noninvasive transcutane-
ous electrical vagal nerve stimulation (t-VNS) of the auricular 
branch of the vagus nerve have been shown to decrease experi-
mental pain and increase GI motility.19,20 Hence, combined 
physiological and electrical modulation of vagal tone, using 
DSB and t-VNS, respectively, may represent an alternative non-
pharmacological treatment modality for pain and GI dysmotility 
in CP. We hypothesized that by increasing parasympathetic 
tone, with combined DSB and VNS, sensory processing of 
pain would be modulated and gastroduodenal motility enhanced 
in comparison to sham stimulation and sham breathing. The 
aims of the study were to study patients with CP to evaluate 
the effects of parasympathetic modulation using DSB and 
t-VNS on 1) experimental musculoskeletal pain thresholds, 2) 
descending pain modulation and 3) gastroduodenal motility.
Patients and methods
Study oversight
This was a randomized, single-blinded, sham-controlled, 
crossover study conducted at the research laboratories of 
Mech-Sense at the Department of Gastroenterology and 
Hepatology, Aalborg University Hospital, Aalborg,  Denmark. 
All patients provided written informed consent after oral and 
written information and adequate consideration. The North 
Denmark Region Committee on Health Research Ethics 
approved the study (N-20090008).
Patients
Twenty patients were recruited from the outpatient clinic of 
our institution. Participants were eligible if diagnosed with 
CP according to the Mayo Clinic Diagnostic Criteria and aged 
18–75 years.21 Other chronic pain conditions, pregnancy and 
allergies to any equipment of the trials (e.g., latex gloves, 
electrodes) were regarded as exclusion criteria. Individual 
patient’s analgesic treatment regimens were not altered dur-
ing the study, and rescue medication for pain flare-ups was 
allowed.
Randomization and blinding
Patients were randomly assigned to receive 60 minutes of 
t-VNS during which they undertook 2 × 10 minutes of DSB, 
or sham procedure, in a crossover design. Randomization was 
employed using a randomization list generated at random-
ization.com. Patients were told that they would receive two 
different forms of nerve stimulation at different locations 
on the ear. Investigators were not blinded to stimulation 
sequence (i.e., single-blinded study). Patients were fasted for 
at least 6 hours prior to each study visit. Visits were planned 
at identical hours of the day and with an interval of minimum 
7 days to reduce any potential carryover effect.22 The study 
protocol is illustrated in Figure 1.
Outcomes measures
There were no specific thresholds predetermined due to the 
exploratory nature of study. The outcome measures were 
merged, as this was an explorative study. Pain was assessed 
using 1) quantitative sensory testing (QST) to document 
changes in pain sensitivity assessed by pressure pain thresh-
olds in bone and muscle and 2) changes in descending pain 
modulation capacity using a conditioned pain modulation 
(CPM) paradigm.17,19 Finally, gastroduodenal motility param-
eters were assessed using 3) a modified version of a real-time 
ultrasonography method to demonstrate changes in motility 
pattern following a standardized drink test.23
Study procedures
An overview of the experimental protocol is provided in 
Figure 2.
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VNS
Noninvasive transcutaneous electrical VNS of the auricular 
branch of the vagal nerve was performed using a commer-
cially available device (Nemos®; cerbomed GmbH, Erlangen, 
Germany). A bipolar stimulation electrode was connected 
to a pocketsize stimulator, and the electrode was placed in 
the left concha. The skin was cleaned with an alcohol wipe 
(Alkoholswabs; Mediq Danmark A/S, Brøndby, Denmark) to 
ensure a sufficient skin contact was made between the elec-
trode and the skin. The stimulation intensity was individually 
adjusted (described later) and ranged from 0.1 mA to 10 mA 
with a pulse width of 250 μs and a stimulation frequency of 
30 Hz. At baseline, patients were familiarized to the stimulus 
for 5 minutes prior to the experimental procedures, where the 
intensity was slowly increased until the optimal intensity was 
reached (i.e., a painful tingling sensation). Due to habituation, 
the intensity was readjusted throughout the study visit. The 
aim of the stimulation was continuous stimulation at the level 
of the intensity of the initial perceptive experience. For sham 
t-VNS, the device was turned 180°, stimulating the outer 
earlobe that does not contain parasympathetic fibers.24 Patients 
received t-VNS, or sham equivalent, for a total of 60 minutes.
Breathing protocol
Physiological vagal stimulation was undertaken with a vali-
dated deep breathing protocol, consisting of breathing at full 
inspiratory capacity for 4 seconds, followed by exhaling to 
forced expiratory vital capacity for 6 seconds, repeated at a 
frequency of 0.1 Hz (i.e., six breaths per minute).20 For the 
sham breathing procedure, patients were asked to breathe 
normally and count their breaths. Patients undertook two 
sessions of 10 minutes of DSB, or sham equivalent, at two 
epochs during the study, i.e., at 15 minutes and 30 minutes.
Experimental procedures
ANS Monitoring
Electrocardiogram (ECG) electrodes (Ambu® BlueSensor 
P; Ambu A/S, Copenhagen, Denmark) were attached at 
the right and left sub-clavicular areas and over the cardiac 
apex. Systolic blood pressure, diastolic blood pressure and 
mean blood pressure were continuously recorded using a 
photoplethysmographic sensory cuff (Nexfin®; BMEYE 
B.V., Amsterdam, the Netherlands) attached to the right 
third digit.25,26 The ECG was recorded using a commercially 
available biosignals acquisition system (NeuroscopeTM; 
Medifit Instruments Limited, Enfield, England; Portapres®; 
Finapres Medical Systems BV, Amsterdam, the Netherlands). 
Based on an R-wave detection algorithm, beat-to-beat, R-R 
interval and heart rate were computed. Cardiac vagal tone 
(CVT) was computed beat-to-beat based on detecting positive 
phase shifts in the R-R interval, a process called “phase-shift 
demodulation”. CVT is measured on a validated linear vagal 
Figure 1 Study protocol.
Abbreviations: t-VNS, noninvasive transcutaneous electrical vagal nerve stimulation; DSB, deep slow breathing; SB, sham breathing.
Randomization
Study protocol
t-VNS and DSB
Crossover
Minimum of
7 days
Visit 1
Sham t-VNS and SB
t-VNS and DSB
Visit 2
Sham t-VNS and SB
Figure 2 Experimental procedures.
Abbreviations: QST, quantitative sensory testing; CPM, conditioned pain modulation; t-VNS, noninvasive transcutaneous electrical vagal nerve stimulation; DSB, deep slow 
breathing; SB, sham breathing.
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scale, where 0 represents full atropinization and is a puta-
tive measure of efferent vagal activity. The Neuroscope also 
derives cardiac sensitivity to the baroreflex (CSB) through 
the incorporation of beat-to-beat R-R intervals with mean 
blood pressure into a 10-second cyclical and is considered 
to be an indirect measure of PNS afferent activity.
QST
Muscle and bone pain pressure thresholds were assessed at 
baseline and after 10 minutes and 25 minutes of intervention. 
Assessments were made on the right quadriceps muscle and 
the tibia bone. A handheld electronic pressure algometer 
(Algometer; Somedic SenseLab AB, Hörby, Sweden) was 
used with a probe surface area of 1 cm2 for muscle stimulation 
and 3 mm2 for bone stimulation. Pressure was increased at a 
rate of 30 kPa/s until the moderate pain threshold was reached 
(i.e., a score of 7 on a 11-point visual analog scale, ranging 
from 0 to 10).27 The patients were instructed to notify the 
investigators when reaching the moderate pain threshold, and 
the corresponding pressure stimulation intensity (kPa) was 
noted. The muscle pressure was also used as the test stimulus 
before, during and after induction of CPM (described later).
CPM
The capacity of descending pain modulation was assessed 
after 40 minutes of intervention using a validated CPM 
paradigm (REF). CPM is a clinically measurable form of 
descending pain modulation that can be induced experimen-
tally by a conditioning stimulus and quantified by applying a 
“test-pain” before and after its induction. Normally, there is 
a 30%–40% fall in the pain evoked by the test stimulus after 
the conditioned stimulation.17,28 We used the cold pressor 
test for conditioning and somatic pressure stimulation of the 
quadriceps muscle as test stimulus.
Cold pressor test
The right hand was immersed in cold water (2.0°C±0.3°C) 
continuously stirred by a pump. The patients were told to 
remove the hand from the water after 2 minutes of immersion 
or earlier if the pain was intolerable. If a patient withdrew 
his/her hand due to intolerable pain prior to this 120 seconds 
mark, the data were still included, as it was considered that 
descending pain control had been induced due to the intensity 
of the conditioning stimulus.17
Pressure stimulation (test stimulus)
The moderate pressure pain threshold was determined 
on the quadriceps muscle 5 cm proximal to the patella 
using the pressure probe described earlier. Pressure 
thresholds were assessed before, during (90 seconds) and 
2 minutes and 5 minutes after the cold pressor test.19 The 
differences in pain thresholds before and after induction 
of cold pressor pain provide a quantitative index of the 
CPM capacity.
Evaluation of gastroduodenal motility parameters
Assessment of gastroduodenal motility was performed 
after 50 minutes of intervention. A powdered tomato 
soup (Knorr® Cup-a-Soup tomato; Unilever, Heilbronn, 
Germany) provided the basis of the liquid meal used for 
the drink test. Ten grams of powdered soup with an energy 
content of 35 kcal (1 g fat, 6 g carbohydrates, 0.5 g dietary 
fibers, 1.25 g protein and 0.75 g salt) was dissolved in 
400 mL of boiled water. The soup was served at a tem-
perature of 40°C. Patients were asked to consume the soup 
over 2 minutes via a straw to reduce any associated air 
swallowing. A modified validated version of a real-time 
ultrasonography method previously described by Kusunoki 
et al19,23 was used for gastroduodenal motility parameters. 
The superior mesenteric vessels and the left liver lobe 
were used as landmarks to obtain a standardized sagittal 
ultrasonic view. For ultrasound investigations, a scanner 
(MyLab™70 XVision; Esaote S.p.A., Genoa, Italy) with a 
standard abdominal probe (CA631; Esaote S.p.A.) was used. 
The patients were instructed in shallow breathing during 
ultrasonography. Still images were stored at baseline (fast-
ing state) and after 1 minute and 15 minutes postprandial 
at relaxed state. Using in-built tool within the scanner, a 
free-hand tracing of the mucosal line of the antrum was 
used for the estimate of antral cross-section areas (CSAs). 
The gastric emptying rate (GER) was defined as
 
GER
antral CSA at  minute
an al CSA at minutes
=
−
×
(
)
1
15tr 100
1antral CSA at  minute
The frequency of antral contractions was defined as the 
number of contractions within a 3-minute interval obtained 
during shallow breathing within the first 5 minutes post-
prandial. This 3-minute interval was recorded and analyzed 
offline avoiding CSA measurements during inspiration. The 
amplitude of antral contractions was calculated from the 
maximal reduction in CSAs and included the mean of three 
full contractions during the 3-minute interval:
 
Amplitude
CSA relaxed CSA contracted
CSA relaxed
=
−( )×100
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The motility index (MI) was defined as the mean amplitude 
multiplied by the frequency of antral contractions per 3 minutes:
 MI amplitude fr uencymean minutes= × eq 3
Statistical analyses
All data are presented as mean±standard deviation (SD) unless 
otherwise indicated. Paired Student’s test or Wilcoxon signed-
rank tests were used to analyze cardiac-derived parameters, QST 
parameters and gastroduodenal motility parameters; results of 
within-group analysis and between-group analysis are reported. 
Bonferroni corrections were applied for multiple comparisons. 
A P-value <0.05 was considered statistically significant. The 
software package STATA version 14.1 (StataCorp LP, College 
Station, TX, USA) was used for statistical calculations.
Results
All 20 enrolled patients completed the study. Patients’ demo-
graphic and clinical characteristics are reported in Table 1. The 
ultrasonographic results of six participants were excluded from 
the analysis of gastroduodenal motility parameters due to air 
ingestion resulting in inadequate visualization of the antrum. 
No adverse events were reported for sham or active t-VNS.
ANS parameters
All cardiac-derived parameters are reported in Table 2. 
Compared to sham stimulation, an increase in CVT was seen 
after t-VNS (3.9±2.3 vs. 6.2±4.8; P=0.02) (Figure 3). Fur-
thermore, the mean blood pressure was significantly lowered 
during t-VNS compared to baseline (86.4±15.5 mmHg vs. 
81.6±16.0 mmHg; P=0.046), while no significant effect on 
diastolic blood pressure was observed.
QST
QST parameters are reported in Table 2. Compared to sham 
stimulation, t-VNS induced no demonstrable differences in 
muscle pressure thresholds (989±336 kPa vs. 991±342 kPa; 
P=0.97) or bone pressure thresholds (161±63 kPa vs. 
170±88 kPa; P=0.67). Also, no differences in thresholds 
were observed between patients on opioids vs. no opioids.
CPM
Prior to the conditioning stimulus (CPM baseline), the pres-
sure pain thresholds were comparable between active and 
sham-stimulated patients (967±274 kPa vs. 887±284 kPa; 
P=0.37). However, a diminished CPM response was seen 
after t-VNS when compared to sham stimulation (7.6±22.5% 
vs. 26.6±18.8%; P=0.02) (Figure 4 and Table 2).
Gastroduodenal motility parameters
No significant changes in gastroduodenal motility param-
eters were observed between t-VNS and sham stimulation: 
gastric emptying rate (36.2±33.8% vs. 23.4±48.4%; P=0.55), 
frequency of antral contractions (4.9±2.4 per 3 minutes vs. 
4.6±3.0 per 3 minutes; P=0.69), amplitude of antral contrac-
tions (42.4±17.3% vs. 42.1±18.5%; P=0.96) and MI (no unit) 
(4.9±3.6 vs. 4.5±3.3; P=0.31).
Discussion
We have provided evidence that in patients with CP, acute 
combined electrical and physiological modulation of vagal tone 
results in an increase in cardiometrically derived parameters of 
vagal tone in comparison to sham stimulation. However, this 
increase was not associated with any alterations in experimental 
somatic pain sensitivity or gastroduodenal motility parameters. 
Table 1 Demographic and clinical characteristics of patients
Variables Values
Male, n (%) 12 (60)
Mean age in years (range) 60.7 (50–78)
Duration of CP in months (range) 92.4 (9–249)
Painful CP (duration of pain >12 weeks), n (%) 14 (70)
Non-painful CP, n (%) 6 (30)
Etiology, n (%)
Toxic/metabolic 11 (55)
Idiopathic 3 (15)
Genetic 0 (0)
Autoimmune 1 (5)
Recurrent 1 (5)
Obstructive 4 (20)
BMI (kg/m2) 23.7 (18.8–36.9)
Diabetes mellitus, n (%)
NIDDM 3 (15)
IDDM 6 (30)
Ongoing alcohol abuse, n (%) 0 (0)
Current smoker, n (%) 13 (65)
Analgesics, n (%)
NSAIDs/paracetamol 14 (70)
Tramadol/codeine 8 (40)
Opioids 7 (35)
Adjuvants (tricyclic antidepressants, gabapentin, 
pregabalin)
3 (15)
Opioid equivalents in mg (range) 33.0 (0–120)
Rescue medication, n (%)
Strong opioids 9 (45)
Weak opioids and/or paracetamol 5 (25)
Complications to CP, n (%) 11 (55)
EPI
Pseudocysts 4 (20)
Bile duct obstruction 2 (10)
Duodenal stenosis 0 (0)
Splenic vein thrombosis 0 (0)
Abbreviations: CP, chronic pancreatitis; BMI, body mass index; NIDDM, non-
insulin-dependent diabetes mellitus; IDDM, insulin-dependent diabetes mellitus; 
NSAIDs, non-steroid anti-inflammatory drugs; EPI, exocrine pancreatic insufficiency.
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 2
9-
M
ay
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Pain Research  2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1352
Juel et al
In addition, a reduction in descending inhibition was seen 
during vagal stimulation as compared to the sham procedure.
The effects of intervention
Vagal activation
Thus, the key result of this study was that t-VNS was able to 
increase the cardiometrically derived parameters of parasym-
pathetic activity in patients with a potentially sensitized pain 
system.17,29,30 In a previous multicenter study of healthy sub-
jects, the normal range for CVT was defined as 1.9–17.8.25 
In another study of patients with functional chest pain of 
presumed esophageal origin, the patients had lower CVT at 
baseline (5.5±0.84 vs. 11.76±1.6) in comparison to healthy 
subjects. By comparison with these studies, our patients had 
an even lower baseline CVT at baseline, thereby potentially 
indicating the existence of an underlying vagal neuropathy.
Motility
Hitherto, t-VNS has not been investigated in patients with 
CP. In a recent study of healthy volunteers, t-VNS increased 
MI and the frequency of antral contractions compared to 
sham stimulation,19 although this was not an effect that we 
saw in this study. In part, this may be a consequence of the 
concomitant analgesic treatment in our patient cohort as well 
as the chronic neuronal changes in patients with CP, whereby 
neural plasticity has been demonstrated both peripherally 
and centrally.16,31,32 In relation to gastroduodenal motility 
assessment, temporal properties and intensity of the t-VNS 
may also play a role with different impact on the vagal tone, 
and other modalities of VNS may be used in future trials.
Pain
The combined effect of acute t-VNS and DSB was insuffi-
cient to induce an analgesic effect arguably in patients with 
an already chronically sensitized pain system. During the 
recent past, a considerable research effort has been afforded 
to investigate the analgesic potential of VNS.33 Tradition-
ally, it is thought that visceral pain afferent information 
is primarily conducted via spinal afferents although there 
is an increasing appreciation that the ANS is involved in 
Table 2 Cardiac-derived parameters and QST in CP patients before and after vagal tone modulation (deep breathing combined with 
t-VNS) and sham stimulation
Test modality Parameter (unit) Baseline Vagal tone  
modulation
Baseline Sham  
modulation
P-valuea
Cardiac-derived 
parameters
Heart rate (beats/min) 74.6±12.3 74.7±10.7 72.5±11.8 69.7±10.1*** 0.0004
Cardiac vagal tone (linear vagal scale) 3.6±2.2 6.2±4.8** 4.1±2.3 3.9±2.3 0.02
Diastolic blood pressure (mmHg) 70.2±14.3 64.0±19.6 68.3±13.9 67.3±14.0 0.36
Systolic blood pressure (mmHg) 118.8±21.1 114.7±20.7 111.7±20.8 120.6±23.4** 0.18
Mean blood pressure (mmHg) 86.4±15.5 81.6±16.0* 82.7±15.7 85.1±15.5 0.21
Quantitative sensory 
testing
Muscle pressure pain threshold (kPa) 939±237 991±342 972±81 989±336 0.97
Bone pressure pain threshold (kPa) 155±57 170±88 989±336 161±63 0.67
Cold pressor test (seconds) – 80±47 – 85±46 0.14
CPM (%) – 7.6±22.5 – 26.6±18.8 0.02
Notes: Data presented as mean ± SD. aVagal tone modulation vs. sham modulation (between-group analysis). Significance of the difference between baseline and vagal tone/
sham modulation (within-group analysis); *P<0.05; **P<0.01; ***P<0.001.
Abbreviations: QST, quantitative sensory testing; CP, chronic pancreatitis; VNS, vagal nerve stimulation; CPM, conditioned pain modulation.
Figure 3 Changes in cardiac-derived parameters boxplot.
Notes: Median and upper and lower quantiles shown. Whiskers represent minimum 
and maximum. Dots represent outliers.
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pain genesis in maintenance across a number of chronic 
pain syndromes including CP.16,18,34 Of note, Botha et al20 
demonstrated that physiological accentuation of vagal tone, 
using DSB, could prevent the development of acid-induced 
esophageal hypersensitivity in a validated model in healthy 
volunteers. Moreover, it was shown that the analgesic effect 
of DSB could be abolished with coadministration of the vago-
lytic agent atropine. In another study of healthy volunteers 
investigating t-VNS, experimental somatic pain thresholds 
increased with short-lasting-t-VNS of the auricular branch of 
the vagal nerve.19 The analgesic effect of VNS is postulated to 
be mediated through stimulation of afferent vagal nerve fibers 
projecting centrally to the nucleus tractus solitarius, raphe 
magnus, locus coeruleus, amygdala and periaqueductal gray. 
All these areas in the central nervous system are involved in 
the descending inhibitory modulation of pain, via the neu-
rotransmitter gamma-aminobuytric acid (GABA).35 Hence, 
the failure to induce pain attenuation in this cohort may be 
due to aberrant central plasticity and/or malfunction within 
the pain system particularly as previous studies of patients 
with CP have shown diminished CPM compared to healthy 
volunteers.17,29 The diminished CPM effect during VNS 
compared to sham stimulation was an unexpected finding. 
In animal studies, it has been suggested that during diabetic 
neuropathy and central sensitization, the GABAergic effect 
can shift from inhibitory to excitatory leading to disinhibi-
tion.36 If this is the case, in a subpopulation of these patients 
having expectedly central sensitization due to chronic pain, 
the unexpected finding of diminished CPM may be partly 
explained. If this is the case, the increased parasympathetic 
tone should then activate the GABAergic system, which due 
to disinhibition responds conversely. Based on these present 
findings, it remains uncertain whether the findings are as 
consequences of peripheral and/or central nervous system 
changes in this cohort of patients with CP.32
Methodological considerations and  
study limitations
CP represents a heterogeneous group of patients, with dif-
ferent pathophysiology and a variable number of coexisting 
diagnoses such as diabetes and different analgesic treatments, 
which evolves with disease duration.
Therefore, the inclusion of patients with both painful 
(n=14) and non-painful CP (n=6) may have influenced the 
results of this study and further investigations of an exclusive 
cohort of patients with painful CP, i.e., presumed sensitized 
pain system, may be of relevance for design of future stud-
ies. We wanted, however, to investigate CP patients, with 
functioning nervous system, and therefore, the investigated 
patients only had a mean duration of CP of 92.4 months 
(Table 1), as we suspected that CP patients with chronic 
pain would have a more complex and sensitized pain system.
Although this study enhanced parasympathetic tone, there 
was no change in any of the algometric end points, thereby 
suggesting that the analgesic potency of the short-term t-VNS 
may not have been powerful enough to induce clinical effects 
in CP patients with a potentially chronic sensitized pain sys-
tem. Otherwise, structural changes in the nervous system due 
to CP, neuroinflammation due to coexisting diabetes and the 
complex nature of CP including several parallel mechanisms 
behind the pain and dysmotility could likely influence the 
outcome. Therefore, other more potent modalities such as 
cervical t-VNS with multiple stimulations, could potentially 
be considered for future studies. Finally, as our design did 
not allow assessment of the physiological or the electrical 
stimulation individually, different approaches, e.g., multiple 
study arms, may be advantageous in the future.
In relation to ultrasound recordings, intra-observer vari-
ance may apply. We, however, aimed to reduce this potential 
bias, as specialists in radiology JBF or AM supervised all 
procedures that were all undertaken by the same operator 
JJ.19 Furthermore, patient instruction was imperative, as the 
procedure needs delicate time managements and focus on not 
consuming air concomitant with ingestion of the soup. Some 
patients, however, did ingest air, which in time obscured the 
visualization of the antrum during analyses of gastroduodenal 
motility parameters in six patients. Other authors experienced 
similar problems in healthy volunteers, even in the pioneering 
study by Kusunoki et al.19,23 This may imply that exclusion of 
patients may easily occur, in particular in patients with already 
impaired gut function, e.g., CP; hence, future trials should 
take this into consideration and power the study for potential 
dropouts due to impaired visualization of the antrum.
Conclusion
This study provides evidence that t-VNS may serve as a 
potential modulator of the parasympathetic nervous system 
in patients with CP. However, in this study, short-term neuro-
modulation was not sufficient to affect musculoskeletal pain 
pressure sensitivity and gastroduodenal motility parameters. 
This could be due to the complex pathophysiology of CP 
pain and dysmotility, including peripheral neuropathy, cen-
tral sensitization and plasticity in central pain processing. 
Future trials in CP are likely to necessitate longer periods 
of neuromodulation and potentially should be conducted as 
a possible add-on to existing analgesic treatment.
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